biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > New Questions

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon Jun 09, 2023 4:09pm

116 Views

Post# 35489203

RE:RE:RE:RE:RE:RE:New Questions

Yeah, I didn't think you were up to answering the questions, poof.

Inflation?

1-in-100 year flood?

"...she tried adding Biodexa"

Adding Biodexa to Bioasis? That's like saying I added a pot of stew to a teaspoon of salt. Bioasis shareholders would have owned only about 5% of Biodexa, and probably others would have owned the xB3 Platform.

Really?? Those are your considered responses?

You're better off copy/pasting!

jd

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale